CPC C12N 15/113 (2013.01) [A61K 31/712 (2013.01); A61K 31/7115 (2013.01); A61K 31/7125 (2013.01); A61K 47/555 (2017.08); A61K 47/61 (2017.08); A61K 47/64 (2017.08); A61K 47/6455 (2017.08); C07H 21/00 (2013.01); C07H 21/02 (2013.01); C07H 21/04 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01)] | 21 Claims |
1. A method of increasing expression of a MECP2 gene in a cell, the method comprising delivering a single stranded oligonucleotide into the cell, wherein the single stranded oligonucleotide
(a) has a sequence 5′-X-Y-Z, wherein X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 3-23 nucleotides in length,
(b) is complementary with at least 10 consecutive nucleotides of a PRC2-associated region of a MECP2 gene, wherein the PRC2-associated region is a region of the MECP2 gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an anti-body that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the MECP2 gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody, and
(c) has at least one nucleotide that is a nucleotide analogue.
|